GRI Bio Announces Partnership With The Respiratory Translational Research Collaboration To Advance Leading NKT Regulation Technology Targeting Earlier In The Inflammatory Cascade To Modulate Disease Progression
Portfolio Pulse from Benzinga Newsdesk
Biotechnology company GRI Bio, Inc. (NASDAQ:GRI) has announced a partnership with the UK's National Institute for Health and Care Research Respiratory Translational Research Collaboration (NIHR Respiratory TRC) to advance its NKT regulation technology for the treatment of inflammatory, fibrotic, and autoimmune diseases. The collaboration will provide GRI Bio with additional data on the role of NKT cells in idiopathic pulmonary fibrosis (IPF) from UK patients. GRI Bio's lead program, GRI-0621, has shown promise in improving fibrosis in multiple disease models and improving liver function tests and other markers of inflammation and injury in patients.
October 17, 2023 | 12:36 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
GRI Bio's partnership with NIHR Respiratory TRC could potentially accelerate the development and approval of its lead program, GRI-0621. This could lead to increased investor confidence and a potential rise in stock price.
The partnership with NIHR Respiratory TRC will provide GRI Bio with additional data on the role of NKT cells in IPF from UK patients, which could potentially accelerate the development and approval of its lead program, GRI-0621. This could lead to increased investor confidence in the company's ability to deliver on its pipeline, potentially leading to a rise in stock price.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100